Illumina Completes $350M Acquisition of SomaLogic's Proteomics Business
Summary
Illumina, Inc. has completed its acquisition of SomaLogic's aptamer-based and functional proteomics business for $350 million in cash, expanding its multiomics portfolio and strengthening its position in the proteomics market.
Key Events
-
Acquisition Completed
Illumina finalized the acquisition of SomaLogic's aptamer-based and functional proteomics business from Standard BioTools Inc. on January 30, 2026.
-
Financial Terms
The transaction involved a cash payment of $350 million at closing, with potential for up to $75 million in milestone payments and royalty streams.
-
Strategic Expansion
This acquisition significantly expands Illumina's multiomics portfolio, integrating proteomics capabilities to drive growth in drug discovery and healthcare.
Analysis
This 8-K announces the finalization of a significant strategic acquisition for Illumina, previously disclosed in June 2025. The completion of the SomaLogic proteomics business acquisition for $350 million in cash, with potential additional milestone payments, marks a material expansion of Illumina's multiomics capabilities. This move is intended to accelerate drug discovery and enhance healthcare by integrating SomaLogic's proteomics technology with Illumina's existing genomics platforms. The acquisition, funded by cash on hand, positions Illumina for growth in the expanding proteomics market and reinforces its leadership in multiomics. Completing this strategic expansion while the company's stock trades near its 52-week high suggests positive market reception to its overall strategy. Investors should monitor the integration process and future financial contributions from this new segment.
At the time of this filing, ILMN was trading at $148.72 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $22.9B. The 52-week trading range was $68.70 to $155.53. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.